The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The efficacy and safety of bezuclastinib in non-advanced systemic mastocytosis
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly comments on the efficacy and safety of bezuclastinib in patients with non-advanced systemic mastocytosis (SM), which is being investigated in the ongoing SUMMIT trial (NCT05186753). At a dose of 100mg, this agent is well-tolerated and highly active and is also being tested in advanced SM (AdvSM) in the APEX trial (NCT04996875). This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
